{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T18:23:33Z","timestamp":1790015013767,"version":"4.0.1"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV-001822"],"award-info":[{"award-number":["INV-001822"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Drugs"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s40272-025-00707-4","type":"journal-article","created":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T12:31:42Z","timestamp":1751459502000},"page":"641-652","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Physiologically Based Pharmacokinetic Modeling-Based Evaluation of Current Carbamazepine and Valproic Acid Dosing Guidelines for Pediatric Epilepsy Treatment"],"prefix":"10.1007","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3584-2318","authenticated-orcid":false,"given":"Joyce E. M.","family":"van der Heijden","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3144-9359","authenticated-orcid":false,"given":"Violette","family":"Gijsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3705-7864","authenticated-orcid":false,"given":"Anne M.","family":"van Uden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1923-2111","authenticated-orcid":false,"given":"Marika","family":"de Hoop-Sommen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4114-5412","authenticated-orcid":false,"given":"Jolien J. M.","family":"Freriksen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9955-0544","authenticated-orcid":false,"given":"Elke","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2599-7540","authenticated-orcid":false,"given":"Rick","family":"Greupink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0502-0647","authenticated-orcid":false,"given":"Saskia N.","family":"de Wildt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,2]]},"reference":[{"key":"707_CR1","doi-asserted-by":"crossref","unstructured":"Aaberg KM, Gunnes N, Bakken IJ, et al. Incidence and prevalence of childhood epilepsy: a nationwide cohort study. Pediatrics. 2017;139(5):e20163908.","DOI":"10.1542\/peds.2016-3908"},{"key":"707_CR2","unstructured":"National Institute for Health and Care Excellence. (2022). Epilepsies in children, young people and adults [NICE guideline no. 217]. London: NICE; 2022. https:\/\/www.nice.org.uk\/guidance\/ng217. Accessed 14 Dec 2023."},{"key":"707_CR3","unstructured":"Federatie Medisch Specialisten. Richtlijnendatabase - Epilepsie. 2020. https:\/\/richtlijnendatabase.nl\/richtlijn\/epilepsie\/startpagina_-_cluster_epilepsie.html. Accessed 14 Dec 2023."},{"key":"707_CR4","unstructured":"Kinderformularium. Kinderformularium - Carbamazepine [updated 15 July 2019]. https:\/\/www.kinderformularium.nl\/geneesmiddel\/202\/carbamazepine. Accessed 14 Dec 2023."},{"key":"707_CR5","unstructured":"Kinderformularium. Kinderformularium - Valpro\u00efnezuur (Natriumvalproaat) [updated 17 October 2020]. https:\/\/www.kinderformularium.nl\/geneesmiddel\/217\/valpronezuur-natriumvalproaat. Accessed 14 Dec 2023."},{"key":"707_CR6","unstructured":"British National Formulary for Children (BNFC). Carbamazepine [Last updated: 21 October 2022]. https:\/\/www.nice.org.uk\/bnfc-uk-only. Accessed 13 Mar 2024."},{"key":"707_CR7","unstructured":"British National Formulary for Children (BNFC). Valproic acid [Last updated: 17 January 2024]. https:\/\/www.nice.org.uk\/bnfc-uk-only. Accessed 13 Mar 2024."},{"issue":"4","key":"707_CR8","doi-asserted-by":"publisher","first-page":"257","DOI":"10.2165\/00003088-199529040-00005","volume":"29","author":"D Battino","year":"1995","unstructured":"Battino D, Estienne M, Avanzini G. Clinical pharmacokinetics of antiepileptic drugs in paediatric patients. Part I: phenobarbital, primidone, valproic acid, ethosuximide and mesuximide. Clin Pharmacokinet. 1995;29(4):257\u201386.","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"707_CR9","doi-asserted-by":"publisher","first-page":"341","DOI":"10.2165\/00003088-199529050-00004","volume":"29","author":"D Battino","year":"1995","unstructured":"Battino D, Estienne M, Avanzini G. Clinical pharmacokinetics of antiepileptic drugs in paediatric patients. Part II. Phenytoin, carbamazepine, sulthiame, lamotrigine, vigabatrin, oxcarbazepine and felbamate. Clin Pharmacokinet. 1995;29(5):341\u201369.","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"707_CR10","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s40272-018-0302-4","volume":"20","author":"G Iapadre","year":"2018","unstructured":"Iapadre G, Balagura G, Zagaroli L, et al. Pharmacokinetics and drug interaction of antiepileptic drugs in children and adolescents. Paediatr Drugs. 2018;20(5):429\u201353.","journal-title":"Paediatr Drugs"},{"issue":"1","key":"707_CR11","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/S0920-1211(02)00251-6","volume":"53","author":"JC Cloyd","year":"2003","unstructured":"Cloyd JC, Dutta S, Cao G, et al. Valproate unbound fraction and distribution volume following rapid infusions in patients with epilepsy. Epilepsy Res. 2003;53(1):19\u201327.","journal-title":"Epilepsy Res"},{"issue":"12","key":"707_CR12","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1056\/NEJMra035092","volume":"349","author":"GL Kearns","year":"2003","unstructured":"Kearns GL, Abdel-Rahman SM, Alander SW, et al. Developmental pharmacology\u2013drug disposition, action, and therapy in infants and children. N Engl J Med. 2003;349(12):1157\u201367.","journal-title":"N Engl J Med"},{"issue":"1","key":"707_CR13","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s40272-022-00535-w","volume":"25","author":"JJM Freriksen","year":"2023","unstructured":"Freriksen JJM, van der Heijden JEM, de Hoop-Sommen MA, et al. Physiologically based pharmacokinetic (PBPK) model-informed dosing guidelines for pediatric clinical care: a pragmatic approach for a special population. Paediatr Drugs. 2023;25(1):5\u201311.","journal-title":"Paediatr Drugs"},{"key":"707_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2020.107541","volume":"211","author":"LFM Verscheijden","year":"2020","unstructured":"Verscheijden LFM, Koenderink JB, Johnson TN, et al. Physiologically-based pharmacokinetic models for children: Starting to reach maturation? Pharmacol Ther. 2020;211: 107541.","journal-title":"Pharmacol Ther"},{"issue":"11","key":"707_CR15","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1002\/jcph.744","volume":"56","author":"Y Mulugeta","year":"2016","unstructured":"Mulugeta Y, Barrett JS, Nelson R, et al. Exposure matching for extrapolation of efficacy in pediatric drug development. J Clin Pharmacol. 2016;56(11):1326\u201334.","journal-title":"J Clin Pharmacol"},{"issue":"7","key":"707_CR16","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1002\/psp4.12967","volume":"12","author":"A Faraj","year":"2023","unstructured":"Faraj A, van Wijk RC, Neuman L, et al. Model-informed pediatric dose selection of marzeptacog alfa (activated): An exposure matching strategy. CPT Pharmacometrics Syst Pharmacol. 2023;12(7):977\u201387.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"2","key":"707_CR17","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1002\/psp4.12577","volume":"10","author":"H Jo","year":"2021","unstructured":"Jo H, Pilla Reddy V, Parkinson J, et al. Model-informed pediatric dose selection for dapagliflozin by incorporating developmental changes. CPT Pharmacometrics Syst Pharmacol. 2021;10(2):108\u201318.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"8","key":"707_CR18","doi-asserted-by":"publisher","first-page":"030006052095228","DOI":"10.1177\/0300060520952281","volume":"48","author":"J Guo","year":"2020","unstructured":"Guo J, Huo Y, Li F, et al. Impact of gender, albumin, and CYP2C19 polymorphisms on valproic acid in Chinese patients: a population pharmacokinetic model. J Int Med Res. 2020;48(8):0300060520952281.","journal-title":"J Int Med Res"},{"issue":"10","key":"707_CR19","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1007\/s40262-022-01171-w","volume":"61","author":"K Lin","year":"2022","unstructured":"Lin K, Cao VFS, Au C, Dahri K. Clinical pharmacokinetic monitoring of free valproic acid levels: a systematic review. Clin Pharmacokinet. 2022;61(10):1345\u201363.","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"707_CR20","doi-asserted-by":"publisher","first-page":"239","DOI":"10.4212\/cjhp.3179","volume":"75","author":"T Brar","year":"2022","unstructured":"Brar T, Mahmoud SH. Role of free valproic acid levels in a patient with severe hypoalbuminemia: a case report. Can J Hosp Pharm. 2022;75(3):239\u201342.","journal-title":"Can J Hosp Pharm"},{"issue":"12","key":"707_CR21","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1007\/s40262-022-01181-8","volume":"61","author":"JEM van der Heijden","year":"2022","unstructured":"van der Heijden JEM, Freriksen JJM, de Hoop-Sommen MA, et al. Feasibility of a pragmatic PBPK modeling approach: towards model-informed dosing in pediatric clinical care. Clin Pharmacokinet. 2022;61(12):1705\u201317.","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"707_CR22","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1002\/cpt.3023","volume":"114","author":"JEM van der Heijden","year":"2023","unstructured":"van der Heijden JEM, Freriksen JJM, de Hoop-Sommen MA, et al. Physiologically-based pharmacokinetic modeling for drug dosing in pediatric patients: a tutorial for a pragmatic approach in clinical care. Clin Pharmacol Ther. 2023;114(5):960\u201371.","journal-title":"Clin Pharmacol Ther"},{"issue":"12","key":"707_CR23","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1002\/psp4.13045","volume":"12","author":"YT Huang","year":"2023","unstructured":"Huang YT, Huang YM, Kung FL, et al. Physiologically based mechanistic insight into differential risk of valproate hepatotoxicity between children and adults: A focus on ontogeny impact. CPT Pharmacometrics Syst Pharmacol. 2023;12(12):1960\u201371.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"707_CR24","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.ejps.2017.10.009","volume":"111","author":"TM Conner","year":"2018","unstructured":"Conner TM, Nikolian VC, Georgoff PE, et al. Physiologically based pharmacokinetic modeling of disposition and drug-drug interactions for valproic acid and divalproex. Eur J Pharm Sci. 2018;111:465\u201381.","journal-title":"Eur J Pharm Sci"},{"issue":"11","key":"707_CR25","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1124\/dmd.115.065920","volume":"43","author":"JE Sager","year":"2015","unstructured":"Sager JE, Yu J, Ragueneau-Majlessi I, Isoherranen N. Physiologically based pharmacokinetic (PBPK) modeling and simulation approaches: a systematic review of published models, applications, and model verification. Drug Metab Dispos. 2015;43(11):1823\u201337.","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"707_CR26","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1097\/FTD.0000000000000546","volume":"40","author":"PN Patsalos","year":"2018","unstructured":"Patsalos PN, Spencer EP, Berry DJ. Therapeutic drug monitoring of antiepileptic drugs in epilepsy: a 2018 update. Ther Drug Monit. 2018;40(5):526\u201348.","journal-title":"Ther Drug Monit"},{"issue":"3","key":"707_CR27","doi-asserted-by":"publisher","first-page":"449","DOI":"10.3109\/15563659309000412","volume":"31","author":"J Hojer","year":"1993","unstructured":"Hojer J, Malmlund HO, Berg A. Clinical features in 28 consecutive cases of laboratory confirmed massive poisoning with carbamazepine alone. J Toxicol Clin Toxicol. 1993;31(3):449\u201358.","journal-title":"J Toxicol Clin Toxicol"},{"issue":"1","key":"707_CR28","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.8367","volume":"12","author":"R Liu","year":"2024","unstructured":"Liu R, Xiao L, Hu Y, et al. Rescue strategies for valproic acid overdose poisoning: Case series and literature review. Clin Case Rep. 2024;12(1): e8367.","journal-title":"Clin Case Rep."},{"issue":"7","key":"707_CR29","first-page":"1239","volume":"49","author":"PN Patsalos","year":"2008","unstructured":"Patsalos PN, Berry DJ, Bourgeois BF, et al. Antiepileptic drugs\u2013best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring. ILAE Commission on Therapeutic Strategies Epilepsia. 2008;49(7):1239\u201376.","journal-title":"ILAE Commission on Therapeutic Strategies. Epilepsia."},{"key":"707_CR30","unstructured":"Nederlandse Vereniging van Ziekenhuisapothekers (NVZA). TDM Monografie - Valpro\u00efnezuur [Last updated: 08-03-2019]. https:\/\/tdm-monografie.org\/valproinezuur\/. Accessed 13 Mar 2024."},{"issue":"2","key":"707_CR31","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1176\/appi.ajp-rj.2019.140203","volume":"14","author":"S Han","year":"2019","unstructured":"Han S. Valproate monitoring in patients with hypoalbuminemia. Am J Psychiatry Residents J. 2019;14(2):8\u20139.","journal-title":"Am J Psychiatry Residents J."},{"issue":"4","key":"707_CR32","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1097\/FPC.0b013e32835ea0b2","volume":"23","author":"Y Ghodke-Puranik","year":"2013","unstructured":"Ghodke-Puranik Y, Thorn CF, Lamba JK, et al. Valproic acid pathway: pharmacokinetics and pharmacodynamics. Pharmacogenet Genomics. 2013;23(4):236\u201341.","journal-title":"Pharmacogenet Genomics"},{"issue":"1","key":"707_CR33","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1111\/j.1528-1157.1992.tb02302.x","volume":"33","author":"T Kondo","year":"1992","unstructured":"Kondo T, Kaneko S, Otani K, et al. Associations between risk factors for valproate hepatotoxicity and altered valproate metabolism. Epilepsia. 1992;33(1):172\u20137.","journal-title":"Epilepsia"},{"issue":"6","key":"707_CR34","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1111\/j.1469-8749.1984.tb08169.x","volume":"26","author":"JF Schoeman","year":"1984","unstructured":"Schoeman JF, Elyas AA, Brett EM, et al. Correlation between plasma carbamazepine-10,11-epoxide concentration and drug side-effects in children with epilepsy. Dev Med Child Neurol. 1984;26(6):756\u201364.","journal-title":"Dev Med Child Neurol"},{"key":"707_CR35","unstructured":"Lexicomp Online, Pediatric and Neonatal Lexi-Drugs Online - Carbamazepine [Last updated 16 August, 2024]. https:\/\/online.lexi.com. Accessed 13 Mar 2024."},{"issue":"Suppl 3","key":"707_CR36","first-page":"S59","volume":"28","author":"RJ Porter","year":"1987","unstructured":"Porter RJ. How to initiate and maintain carbamazepine therapy in children and adults. Epilepsia. 1987;28(Suppl 3):S59-63.","journal-title":"Epilepsia"},{"issue":"Suppl 3","key":"707_CR37","first-page":"S64","volume":"28","author":"JM Pellock","year":"1987","unstructured":"Pellock JM. Carbamazepine side effects in children and adults. Epilepsia. 1987;28(Suppl 3):S64-70.","journal-title":"Epilepsia"},{"issue":"3","key":"707_CR38","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S0022-3476(85)80689-2","volume":"106","author":"M Furlanut","year":"1985","unstructured":"Furlanut M, Montanari G, Bonin P, et al. Carbamazepine and carbamazepine-10,11-epoxide serum concentrations in epileptic children. J Pediatr. 1985;106(3):491\u20135.","journal-title":"J Pediatr"},{"issue":"3","key":"707_CR39","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1097\/00007691-198609000-00009","volume":"8","author":"AA Elyas","year":"1986","unstructured":"Elyas AA, Patsalos PN, Agbato OA, et al. Factors influencing simultaneous concentrations of total and free carbamazepine and carbamazepine-10, 11-epoxide in serum of children with epilepsy. Ther Drug Monit. 1986;8(3):288\u201392.","journal-title":"Ther Drug Monit"},{"issue":"6","key":"707_CR40","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1111\/j.1469-8749.1984.tb08168.x","volume":"26","author":"JF Schoeman","year":"1984","unstructured":"Schoeman JF, Elyas AA, Brett EM, et al. Altered ratio of carbamazepine-10,11-epoxide\/carbamazepine in plasma of children: evidence of anticonvulsant drug interaction. Dev Med Child Neurol. 1984;26(6):749\u201355.","journal-title":"Dev Med Child Neurol"},{"issue":"4","key":"707_CR41","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1055\/s-2008-1073024","volume":"25","author":"R Korinthenberg","year":"1994","unstructured":"Korinthenberg R, Haug C, Hannak D. The metabolization of carbamazepine to CBZ-10,11-epoxide in children from the newborn age to adolescence. Neuropediatrics. 1994;25(4):214\u20136.","journal-title":"Neuropediatrics"},{"issue":"2","key":"707_CR42","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1002\/ana.410250215","volume":"25","author":"WH Theodore","year":"1989","unstructured":"Theodore WH, Narang PK, Holmes MD, et al. Carbamazepine and its epoxide: relation of plasma levels to toxicity and seizure control. Ann Neurol. 1989;25(2):194\u20136.","journal-title":"Ann Neurol"},{"issue":"3","key":"707_CR43","doi-asserted-by":"publisher","first-page":"177","DOI":"10.2165\/00003088-198611030-00001","volume":"11","author":"L Bertilsson","year":"1986","unstructured":"Bertilsson L, Tomson T. Clinical pharmacokinetics and pharmacological effects of carbamazepine and carbamazepine-10,11-epoxide. An update Clin Pharmacokinet. 1986;11(3):177\u201398.","journal-title":"An update. Clin Pharmacokinet."},{"issue":"2","key":"707_CR44","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1111\/j.1432-1033.1985.tb09107.x","volume":"151","author":"T Cresteil","year":"1985","unstructured":"Cresteil T, Beaune P, Kremers P, et al. Immunoquantification of epoxide hydrolase and cytochrome P-450 isozymes in fetal and adult human liver microsomes. Eur J Biochem. 1985;151(2):345\u201350.","journal-title":"Eur J Biochem"},{"issue":"5","key":"707_CR45","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1159\/000137807","volume":"26","author":"GM Pacifici","year":"2008","unstructured":"Pacifici GM, Rane A. Epoxide hydrolase in human fetal liver. Pharmacology. 2008;26(5):241\u20138.","journal-title":"Pharmacology"},{"issue":"1","key":"707_CR46","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/S0022-3565(25)38662-3","volume":"269","author":"CJ Omiecinski","year":"1994","unstructured":"Omiecinski CJ, Aicher L, Swenson L. Developmental expression of human microsomal epoxide hydrolase. J Pharmacol Exp Ther. 1994;269(1):417\u201323.","journal-title":"J Pharmacol Exp Ther"},{"issue":"4","key":"707_CR47","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1111\/j.1528-1157.1985.tb05657.x","volume":"26","author":"R Riva","year":"1985","unstructured":"Riva R, Contin M, Albani F, et al. Free and total serum concentrations of carbamazepine and carbamazepine-10,11-epoxide in infancy and childhood. Epilepsia. 1985;26(4):320\u20132.","journal-title":"Epilepsia"},{"issue":"4","key":"707_CR48","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1592\/phco.27.4.519","volume":"27","author":"LM Taylor","year":"2007","unstructured":"Taylor LM, Farzam F, Cook AM, et al. Clinical utility of a continuous intravenous infusion of valproic acid in pediatric patients. Pharmacotherapy. 2007;27(4):519\u201325.","journal-title":"Pharmacotherapy"},{"issue":"1","key":"707_CR49","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1046\/j.1365-2710.1999.00202.x","volume":"24","author":"BB Serrano","year":"1999","unstructured":"Serrano BB, Garc\u00eda S\u00e1nchez MJ, Otero MJ, et al. Valproate population pharmacokinetics in children. J Clin Pharm Ther. 1999;24(1):73\u201380.","journal-title":"J Clin Pharm Ther"},{"issue":"5","key":"707_CR50","doi-asserted-by":"publisher","first-page":"447","DOI":"10.2165\/00003088-198308050-00005","volume":"8","author":"K Hall","year":"1983","unstructured":"Hall K, Otten N, Irvine-Meek J, et al. First-dose and steady-state pharmacokinetics of valproic acid in children with seizures. Clin Pharmacokinet. 1983;8(5):447\u201355.","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"707_CR51","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/BF00315328","volume":"238","author":"L Herngren","year":"1991","unstructured":"Herngren L, Lundberg B, Nerg\u00e5rdh A. Pharmacokinetics of total and free valproic acid during monotherapy in infants. J Neurol. 1991;238(6):315\u20139.","journal-title":"J Neurol"},{"issue":"3","key":"707_CR52","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1097\/FTD.0000000000000405","volume":"39","author":"E Wallenburg","year":"2017","unstructured":"Wallenburg E, Klok B, de Jong K, et al. Monitoring protein-unbound valproic acid serum concentrations in clinical practice. Ther Drug Monit. 2017;39(3):269\u201372.","journal-title":"Ther Drug Monit"},{"issue":"3","key":"707_CR53","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s40262-014-0212-8","volume":"54","author":"J Ding","year":"2015","unstructured":"Ding J, Wang Y, Lin W, et al. A population pharmacokinetic model of valproic acid in pediatric patients with epilepsy: a non-linear pharmacokinetic model based on protein-binding saturation. Clin Pharmacokinet. 2015;54(3):305\u201317.","journal-title":"Clin Pharmacokinet"},{"issue":"7","key":"707_CR54","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1007\/s00228-020-03080-y","volume":"77","author":"X Gu","year":"2021","unstructured":"Gu X, Zhu M, Sheng C, et al. Population pharmacokinetics of unbound valproic acid in pediatric epilepsy patients in China: a protein binding model. Eur J Clin Pharmacol. 2021;77(7):999\u20131009.","journal-title":"Eur J Clin Pharmacol"},{"issue":"3","key":"707_CR55","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1002\/jcph.1333","volume":"59","author":"M Tauzin","year":"2019","unstructured":"Tauzin M, Tr\u00e9luyer JM, Nabbout R, et al. Simulations of valproate doses based on an external evaluation of pediatric population pharmacokinetic models. J Clin Pharmacol. 2019;59(3):406\u201317.","journal-title":"J Clin Pharmacol"},{"key":"707_CR56","unstructured":"Nederlandse Vereniging van Ziekenhuisapothekers (NVZA). TDM Monografie - Carbamazepine [Last updated: 25-02-2021]. https:\/\/tdm-monografie.org\/carbamazepine\/. Accessed 13 Mar 2024."},{"issue":"11","key":"707_CR57","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1007\/s40262-013-0087-0","volume":"52","author":"PN Patsalos","year":"2013","unstructured":"Patsalos PN. Drug interactions with the newer antiepileptic drugs (AEDs)\u2013part 1: pharmacokinetic and pharmacodynamic interactions between AEDs. Clin Pharmacokinet. 2013;52(11):927\u201366.","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"707_CR58","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s13318-018-0532-4","volume":"44","author":"TM Conner","year":"2019","unstructured":"Conner TM, Reed RC, Zhang T. A physiologically based pharmacokinetic model for optimally profiling lamotrigine disposition and drug-drug interactions. Eur J Drug Metab Pharmacokinet. 2019;44(3):389\u2013408.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"3","key":"707_CR59","doi-asserted-by":"publisher","first-page":"237","DOI":"10.2165\/00003088-199120030-00005","volume":"20","author":"R Hartley","year":"1991","unstructured":"Hartley R, Forsythe WI, McLain B, et al. Daily variations in steady-state plasma concentrations of carbamazepine and its metabolites in epileptic children. Clin Pharmacokinet. 1991;20(3):237\u201346.","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"707_CR60","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.pediatrneurol.2003.12.006","volume":"30","author":"S Dutta","year":"2004","unstructured":"Dutta S, Zhang Y, Conway JM, et al. Divalproex-ER pharmacokinetics in older children and adolescents. Pediatr Neurol. 2004;30(5):330\u20137.","journal-title":"Pediatr Neurol"}],"container-title":["Pediatric Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-025-00707-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40272-025-00707-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-025-00707-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T01:07:12Z","timestamp":1757207232000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40272-025-00707-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,2]]},"references-count":60,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["707"],"URL":"https:\/\/doi.org\/10.1007\/s40272-025-00707-4","relation":{},"ISSN":["1174-5878","1179-2019"],"issn-type":[{"value":"1174-5878","type":"print"},{"value":"1179-2019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,2]]},"assertion":[{"value":"2 June 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This publication is based on research funded by the Bill & Melinda Gates Foundation (INV-001822). The findings and conclusions contained within are those of the authors and do not necessarily reflect positions or policies of the Bill & Melinda Gates Foundation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Prof. dr. de Wildt is a paid consultant for Khondrion and an editorial board member of Pediatric Drugs so was not involved in the selection of peer reviewers for the manuscript or any of the subsequent editorial decisions. All other authors have no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"Ethical approval was not required for this study as it was based solely on computer-based simulations and did not involve any human or animal subjects.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Consent was not required for this study as it was based solely on computer-based simulations and did not involve any human or animal subjects.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"The raw data supporting the conclusions of this article will be made available by the authors without undue reservation.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material:"}},{"value":"Simcyp PBPK software version 21 and version 22 (Certara UK Limited, Simcyp Division, Sheffield, UK).","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Publish"}},{"value":"JH: Conceptualization, data curation, writing \u2013 original draft, and writing \u2013 review and editing. VG, JF, and EJ: Writing \u2013 review & editing. AU and MH-S: Data curation and writing \u2013 review & editing. RG and SW: Conceptualization and writing \u2013 review & editing.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}